Status:
COMPLETED
A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.
Lead Sponsor:
GlaxoSmithKline
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
This study will investigate the safety and tolerability of inhaled doses of GSK233705 with a new formulation.
Detailed Description
A single-centre, randomized, double-blind placebo-controlled, dose-ascending, cross-over study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GS...
Eligibility Criteria
Inclusion
- Healthy male subjects 18-55 years old
- Non-Smokers
Exclusion
- Any subject with breathing problems.
- High blood pressure and heart abnormalities.
- Any subjects currently taking prescription and non-prescription medications.
Key Trial Info
Start Date :
March 9 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 16 2007
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00453687
Start Date
March 9 2007
End Date
May 16 2007
Last Update
August 7 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Baltimore, Maryland, United States, 21225